HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...
Zacks.com on MSN4d
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
News242d
A jab that could protect against HIV for a year at a time
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...
Investing6d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
JPMorgan sees CDC funding report not impacting Gilead story
JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...
Investor's Business Daily on MSN5d
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...
pharmaphorum1d
Gilead’s twice-yearly HIV PrEP 100% effective, says study
Gilead Sciences’ already dominant position in ... and showed a subcutaneous injection with lenacapavir every six months was more effective than its widely-used oral PrEP drug Truvada ...